This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) strength in business raises optimism about the stock.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)
by Zacks Equity Research
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cardinal Health (CAH) Gets FDA Warning for Monoject Syringes
by Zacks Equity Research
The FDA is alerting healthcare providers and facilities against the use of Cardinal Health's (CAH) Monoject syringes with syringe pumps and PCS pumps.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
by Zacks Equity Research
Here is how Arch Therapeutics, Inc. (ARTH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.
Why You Should Add Integer Holdings (ITGR) to Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Is Invesco Russell 1000 Dynamic Multifactor ETF (OMFL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OMFL
Zacks.com featured highlights Cboe Global, Parker-Hannifin, Microsoft, FedEx and Cardinal Health
by Zacks Equity Research
Cboe Global, Parker-Hannifin, Microsoft, FedEx and Cardinal Health have been highlighted in this Screen of The Week article.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.
5 Top Dividend Growth Stocks for Your Portfolio
by Sweta Killa
Cboe Global Markets (CBOE), Parker-Hannifin (PH), Microsoft (MSFT), FedEx (FDX) and Cardinal Health (CAH) could be solid choices for your portfolio.
4 Growth Stocks to Take Advantage of the November Rally
by Tirthankar Chakraborty
With things looking up for the stock market this November, investing in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cardinal Health (CAH) and Runway Growth Finance (RWAY) seems prudent.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal Health (CAH) Launches Surgical Gown for Safe Surgery
by Zacks Equity Research
Cardinal Health's (CAH) SmartGown EDGE Breathable Surgical Gown will enable clinical teams to focus on delivering safe patient care by reducing instrument handoffs and contamination.
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.